Sign Out
Hypersensitivity to the active substances or to any of the excipients listed in Description.
Co-administration with medicinal products that are strong cytochrome P450 CYP3A enzyme inducers is contraindicated as significant decreases in doravirine plasma concentrations are expected to occur, which may decrease the effectiveness of Delstrigo (see Precautions and Interactions). These medicinal products include, but are not limited to the following: carbamazepine, oxcarbazepine, phenobarbital, phenytoin; rifampicin, rifapentine; St. John's wort (Hypericum perforatum); mitotane; enzalutamide; lumacaftor.
Continue with Google